Fecha de publicación

2026-02-26T10:43:15Z

2026-02-26T10:43:15Z

2025-07-31

2026-02-26T10:43:15Z



Resumen

COPD is the third leading cause of death globally and remains a major public health burden. Despite its substantial impact, effective prevention remains challenging. COPD is currently defined as having FEV<sub>1</sub>/FVC below lower limit of normal or 0.7 in a person with known risk factors. However, this formal diagnosis occurs only after significant loss of lung function and the onset of persistent symptoms. These symptoms, rather than pathophysiological changes, are what typically prompt patients to seek medical care. Even then, many are not offered spirometry, further delaying diagnosis until acute exacerbations or a level of dyspnoea that impacts daily life prompt clinical attention. By this point, more than 50% of individual’s FEV<sub>1</sub> has often been lost and treatment becomes largely palliative. This situation highlights a pressing need for earlier identification of lung damage associated to a later diagnosis of COPD; this is needed in its early “silent” phase, when there might be an opportunity to change the course of disease with preventive interventions.

Tipo de documento

Artículo


Versión aceptada

Lengua

Inglés

Publicado por

Elsevier Ltd.

Documentos relacionados

Versió postprint del document publicat a: https://doi.org/10.1016/S2213-2600(25)00236-X

The Lancet Respiratory Medicine, 2025, vol. 13, num.9, p. 778-781

https://doi.org/10.1016/S2213-2600(25)00236-X

Citación recomendada

Esta citación se ha generado automáticamente.

Derechos

cc-by-nc-nd (c) Elsevier Ltd., 2025

http://creativecommons.org/licenses/by-nc-nd/4.0/

Este ítem aparece en la(s) siguiente(s) colección(ones)